



EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES
COMMONWEALTH OF MASSACHUSETTS
OFFICE OF MEDICAID
ONE ASHBURTON PLACE, BOSTON, MA 02108



MAURA T. HEALEY
GOVERNOR

KIAME MAHANIAH, MD, MBA
SECRETARY

KIMBERLEY DRISCOLL
LIEUTENANT GOVERNOR

MIKE LEVINE
UNDERSECRETARY
FOR MASSHEALTH

June 9, 2026

Chair, Michael Rodrigues
Senate Committee on Ways and Means
State House, Room 212
Boston, MA 02133

Chair, Aaron Michlewitz
House Committee on Ways and Means
State House, Room 243
Boston, MA 02133

Senate Chair, Cindy Friedman
Joint Committee on Health Care Financing
State House, Room 313
Boston, MA 02133

House Chair, John Lawn Jr.
Joint Committee on Health Care Financing
State House, Room 236
Boston, MA 02133

Dear Chairs Rodrigues, Michlewitz, Friedman, and Lawn,

In July 2019, MassHealth received the authority to directly negotiate with drug manufacturers for supplemental rebate agreements through Section 46 of Chapter 41 of the Acts of 2019 (the Fiscal Year 2020 budget), codified in Chapter 118E, Section 12A of the Massachusetts General Laws. This authority has dramatically increased the pace at which MassHealth can enter into these agreements. As of July 1, 2025, MassHealth has active agreements on supplemental rebate contracts with 32 manufacturers for 83 drugs with a total annual incremental savings of approximately \$584M. The 33 manufacturers are listed in the table below.¹

Contracts with six manufacturers (covering 9 drugs) qualify as value-based payment (VBP) agreements. These agreements tie rebate amount to outcomes data, including efficacy data and utilization data, or use alternative payment methodologies. For instance, under certain VBP agreements, if a drug is ineffective or if extended therapy is required, MassHealth may receive a portion or all of its payment back. This remains an exciting development, as it allows drug manufacturers to stand behind their products and be financially responsible for clinical outcomes.

The table below details agreements finalized through direct negotiations to date.

¹ As a reminder, there were agreements with 21 manufacturers for 72 drugs in FY24 (reported on October 2024) with a total annual incremental savings of approximately \$450M. Compared to the last report, there has been an increase in the number of contracts, as well as additional savings for existing contracts based on increased utilization.

Manufacturer	Drugs with Directly Negotiated Supplemental Rebate Agreements Drug Name (Initial Year of Directly Negotiated Contract)
AbbVie	Humira (2019), Mavyret (2019), Norvir (2019), Qulipta (2024), Skyrizi (2025), Ubrelyvy (2022), Vraylar (2022)
Alkermes	Aristada (2019), Vivitrol (2024)
Alnylam	Amvuttra (2023), Givlaari (2020), Onpattro (2020), Oxlumio (2023)
Amgen	Enbrel (2019)
Amphastar	Baqsimi (2024)
Arcutis	Zoryve (2025)
Ascendis	Skytrofa (2024)
Asegua	Ledipasvir-Sofosbuvir (2019), Sofosbuvir-Velpatasvir (2019)
AstraZeneca	Symbicort (2024)
Bayer	Jivi (2022), Kovaltry (2022)
Biogen	Zuruvae (2024)
Braeburn Inc.	Brixadi (2025)
Eli Lilly	Ebglyss (2025), Emgality (2020), Mounjaro (2025), Omvoh (2025), Taltz (2020) and Trulicity (2020), Zepbound (2024)
Genentech	Hemlibra (2024)
Gilead	Biktarvy (2019), Descovy (2019), Epclusa (2019), Genvoya (2019), Harvoni (2019), Odefsey (2019), Vemlidy (2023)
Hikma	Kloxxado (2022)
Incyte	Opzelura (2025)
Indivior	Perseris ER (2023), Sublocade (2021), Suboxone Film (2019)
Janssen	Invega Hafyera (2022), Invega Sustenna (2021), Invega Trinza (2020), Prezcobix (2020), Stelara (2021), Symtuza (2020)
LEO Pharma	Adbry (2025)
Merck	Delstrigo (2020), Pifeltro (2020)
Novartis	Zolgensma (2019)
Novo Nordisk	Sogroya (2025)
Pfizer	Benefix (2020), Eucrisa (2020), Genotropin (2020), Ibrance (2020), Nurtec ODT (2024), Paxlovid (2025), Xyntha (2020)
Recordati Rare Disease	Carbaglu (2022)
Sanofi	Dupixent (2022), Lantus (2024)
Takeda	Adderall XR (2024)
Teva	Ajovy (2020), Uzedy ER (2023)
Tolmar	Fensolvi (2025)
Verrica	Ycanth (2025)
Vertex	Alyftrek (2025), Casgevy (2024) ² , Journavx (2025), Kalydeco (2021), Orkambi (2021), Symdeko (2021) Trikafta (2021)
ViiV	Apretude (2023), Cabenuva (2021), Dovato (2019), Juluca (2019), Rukobia (2019), Triumeq (2019)

² MassHealth has two distinct value-based contracts with Vertex for Casgevy.

Please contact Sarah Nordberg at Sarah.Nordberg@mass.gov if you have any questions.

Sincerely,

A handwritten signature in black ink that reads "Mike Levine". The signature is written in a cursive, flowing style.

Mike Levine

cc: Kiame Mahaniah, MD, MBA